BioMarin Pharmaceuticals
BMRN
500 hedge funds and large institutions have $15B invested in BioMarin Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 80 funds opening new positions, 184 increasing their positions, 164 reducing their positions, and 43 closing their positions.
86% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 43
38% more call options, than puts
Call options by funds: $139M | Put options by funds: $101M
12% more repeat investments, than reductions
Existing positions increased: 184 | Existing positions reduced: 164
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
7% more funds holding
Funds holding: 467 → 500 (+33)
1.87% more ownership
Funds ownership: 96.62% → 98.49% (+1.9%)
2% more capital invested
Capital invested by funds: $14.7B → $15B (+$291M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Winslow Capital Management
Minneapolis,
Minnesota
|
+$185M |
| 2 |
BlackRock
New York
|
+$132M |
| 3 |
Primecap Management
Pasadena,
California
|
+$128M |
| 4 |
Jennison Associates
New York
|
+$101M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$94.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$215M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$153M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$137M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$60.5M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$41.1M |
BMRN Hedge Fund Activity: Q1 2020 in Review
500 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q1 2020, worth a combined $15B — up 2% from $14.7B a quarter earlier.
Buyers outnumbered sellers: 80 funds opened new BMRN positions and 43 closed out — a net gain of 37 holders — while 184 added to existing stakes and 164 trimmed.
The largest buyer was Winslow Capital Management, opening a new position worth an estimated $185M. The largest seller was Capital World Investors, cutting an estimated $215M.
- 500 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q1 2020, up from 467 in Q4 2019.
- Funds reported $15B of BioMarin Pharmaceuticals stock for Q1 2020, up 2% quarter-over-quarter.
- 80 funds opened new BioMarin Pharmaceuticals positions in Q1 2020 and 43 closed out, a net change of +37 holders.
- The largest BioMarin Pharmaceuticals buyer in Q1 2020 was Winslow Capital Management, an estimated $185M added.
- The largest BioMarin Pharmaceuticals seller in Q1 2020 was Capital World Investors, an estimated $215M sold.
Based on aggregated 13F filings for Q1 2020.